使用分子工具识别惰性乳腺癌患者并随访超20年
该研究为一项随机临床试验的二次分析,纳入1976至1990年绝经后淋巴结阴性乳腺癌患者,评估MammaPrint 70基因表达评分超低风险阈值与惰性行为的关系。中位随访超20年,652例可评分患者中98例(15%)为超低风险,超低风险患者20年乳腺癌特异性生存率为97%,未治疗者为94%。
要点
- MammaPrint 70基因检测可识别术后长期乳腺癌死亡风险极低的超低风险患者。
- 超低风险患者20年乳腺癌特异性生存率为97%,未治疗者为94%。
- 70基因高风险和低风险(非超低风险)患者疾病特异性死亡风险显著高于超低风险患者。
核心结论
- 70基因MammaPrint检测的超低风险阈值可识别仅手术后长期全身性乳腺癌死亡风险极低的患者。
研究设计与样本
- 此为一项他莫昔芬对比无全身治疗随机临床试验的二次分析,随访超过20年。
- 研究纳入1976至1990年斯德哥尔摩他莫昔芬试验(STO-3)中经临床发现的淋巴结阴性、接受乳房切除术或肿块切除加放疗的绝经后乳腺癌患者。
- 免疫组化标志物分析纳入727例女性,Agilent微阵列用于MammaPrint风险评分纳入652例女性,样本为福尔马林固定石蜡包埋的原发肿瘤块。
主要发现
- 在652例可进行MammaPrint评分的女性中(中位年龄62.8岁),377例(58%)为MammaPrint低风险,275例(42%)为高风险,98例(15%)为超低风险。
- 20年时,经Cox分析,70基因高风险和低风险(非超低风险)肿瘤女性相比超低风险患者的疾病特异性死亡风险显著更高,风险比分别为4.73(95%CI,1.38-16.22)和4.54(95%CI,1.40-14.80)。
- 超低风险他莫昔芬治疗组15年时无死亡,这些患者20年疾病特异性生存率为97%,而未治疗患者生存率为94%。
- 递归分割分析确定超低风险为良好结局的最显著预测因子。
- 在「非超低风险」肿瘤中,肿瘤大小大于2 cm是结局的最强预测因子。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The frequency of cancers with indolent behavior has increased with screening. Better tools to identify indolent tumors are needed to avoid overtreatment. OBJECTIVE: To determine if a multigene classifier is associated with indolent behavior of invasive breast cancers in women followed for 2 decades. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of a randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up. An indolent threshold (ultralow risk) of the US Food and Drug Administration-cleared MammaPrint 70-gene expression score was established above which no breast cancer deaths occurred after 15 years in the absence of systemic therapy. Immunohistochemical markers (n = 727 women) and Agilent microarrays, for MammaPrint risk scoring (n = 652 women), were performed from formalin-fixed paraffin-embedded primary tumor blocks. Participants were postmenopausal women with clinically detected node-negative breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the Stockholm tamoxifen (STO-3) trial, 1976 to 1990. EXPOSURES: After 2 years of tamoxifen vs no systemic therapy, regardless of hormone receptor status, patients without relapse who reconsented were further randomized to 3 additional years or none. MAIN OUTCOMES AND MEASURES: Breast cancer-specific survival assessed by Kaplan-Meier analyses and multivariate Cox proportional hazard modeling, adjusted for treatment, patient age, year of diagnosis, tumor size, grade, hormone receptors, and ERBB2/HER2 and Ki67 status. RESULTS: In this secondary analysis of node-negative postmenopausal women, conducted in the era before mammography screening, among the 652 women with MammaPrint scoring available (median age, 62.8 years of age), 377 (58%) and 275 (42%) were MammaPrint low and high risk, respectively, while 98 (15%) were ultralow risk. At 20 years, women with 70-gene high and low tumors but not ultralow tumors had a significantly higher risk of disease-specific death compared with ultralow-risk patients by Cox analysis (hazard ratios, 4.73 [95% CI, 1.38-16.22] and 4.54 [95% CI, 1.40-14.80], respectively). There were no deaths in the ultralow-risk tamoxifen-treated arm at 15 years, and these patients had a 20-year disease-specific survival rate of 97%, whereas for untreated patients the survival rate was 94%. Recursive partitioning identified ultralow risk as the most significant predictor of good outcome. In tumors "not ultralow risk," tumor size greater than 2 cm was the most predictive of outcome. CONCLUSIONS AND RELEVANCE: The ultralow-risk threshold of the 70-gene MammaPrint assay can identify patients whose long-term systemic risk of death from breast cancer after surgery alone is exceedingly low.
引用
- Esserman LJ, Yau C, Thompson CK, et al. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. JAMA Oncol. 2017. PMID: 28662222. doi:10.1001/jamaoncol.2017.1261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。